In 2014, MAPS spun out a different division to immediate study and get ready for an eventual FDA software, which it submitted at the end of very last year. In early 2024, that offshoot was renamed Lykos Therapeutics.Fears about protection challenges, Unwanted effects, and abuse are more likely to pop up for other psychedelics also, states Mason Mar